Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo
-
Published:2012-07-26
Issue:1
Volume:12
Page:
-
ISSN:1472-6882
-
Container-title:BMC Complementary and Alternative Medicine
-
language:en
-
Short-container-title:BMC Complement Altern Med
Author:
Đorđić Marija,Matić Ivana Z,Filipović-Lješković Ivana,Džodić Radan,Šašić Miomir,Erić-Nikolić Aleksandra,Vuletić Ana,Kolundžija Branka,Damjanović Ana,Grozdanić Nađa,Nikolić Srđan,Pralica Janko,Dobrosavljević Danijela,Rašković Sanvila,Andrejević Slađana,Juranić Zorica
Abstract
Abstract
Background
The aim of this study was to determine the presence and the intensity of humoral immunity to melanoma-associated antigens: tyrosinase and melanin, in patients with melanoma, in persons with vitiligo and in control healthy people.
Methods
The study involved 63 patients with melanoma and 19 persons with vitiligo. Control group consisted up to 41 healthy volunteers. Mushroom tyrosinase and synthetic melanin were used as the antigens.
Results
ELISA test showed significantly (p < 0.0000004 and p < 0.04) lower levels of IgM anti-tyrosinase autoantibodies, in melanoma and vitiligo patients respectively, compared to controls.
Although there was no significant difference between the levels of IgA anti-melanin autoantibodies in melanoma or vitiligo patients in comparison with controls, the enhanced concentrations of anti-melanin IgA autoantibodies were preferentially found in melanoma patients with metastatic disease. Significantly high percentage in the Fc alphaRI (CD89) positive cells was determined in melanoma patients (p < 0.002 and p < 0.008) in comparison to that found in healthy people or in patients with vitiligo, in the already mentioned order, pointing that IgA dependent cellular cytotoxicity is not important for the immune action against melanoma, even more that it is included in some immune suppression.
Levels of IgG autoantibodies to mentioned antigens in melanoma patients although low were not significantly lower from controls. These findings analyzed together with the statistically significant low percentage of FcgammaRIII, (CD16) positive immunocompetent cells (p < 0.0007 and p < 0.003), which was found in patients with melanoma compared with healthy or vitiligo people respectively, and statistically significant low percentage of (CD16 + CD56+) natural killer (NK) cells (p < 0.005) found in melanoma patients in comparison to healthy controls pointed to the low probability for anti-melanoma IgG mediated, antibody mediated cellular cytotoxicity, (ADCC) and NK cytotoxicity. Moreover the ratio of the percentages of granulocytes and percentage of lymphocytes was statistically higher in patients with melanoma in relation to healthy people as well as to people with vitiligo (p < 0.0007 and p < 0.05 respectively).
Conclusion
Autoantibodies to tyrosinase and to melanin which are found even in healthy people, point that consummation of edible mushrooms that carry the antigen tyrosinase and melanin, could influence the humoral anti-melanoma immune response.
Levels of different immunoglobulin classes of anti-melanin and anti-tyrosinase antibodies varied depending on the presence and the stage of studied diseases. Besides, the statistically enhanced ratio of the percentages of granulocytes and percentage of lymphocytes, together with statistically decreased percentage of NK cells is found in analyzed melanoma patients.
Publisher
Springer Science and Business Media LLC
Subject
Complementary and alternative medicine,General Medicine
Reference36 articles.
1. Kalialis LV, Drzewiecki KT, Klyver H: Spontaneous regression of metastases from melanoma: review of the literature. Melanoma Res. 2009, 19: 275-282. 10.1097/CMR.0b013e32832eabd5. 2. Schadendorf D, Algarra SM, Bastholt L, Cinat G, Dreno B, Eggermont AM, Espinosa E, Guo J, Hauschild A, Petrella T, Schachter J, Hersey P: Immunotherapy of distant metastatic disease. Ann Oncol. 2009, 20 (Suppl 6): 41-50. 3. Carretero R, Wang E, Rodriguez AI, Reinboth J, Ascierto ML, Engle AM, Liu H, Camacho FM, Marincola FM, Garrido F, Cabrera T: Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer. 2011, 10.1002/ijc.26471. 4. Turcotte S, Rosenberg SA: Immunotherapy for metastatic solid cancers. Adv Surg. 2011, 45: 341-360. 10.1016/j.yasu.2011.04.003. 5. Damian DL, Shannon KF, Saw RP, Thompson JF: Topical diphencyprone immunotherapy for cutaneous metastatic melanoma. Australas J Dermatol. 2009, 50: 266-271. 10.1111/j.1440-0960.2009.00556.x.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|